Triplet Not Always Better Than Doublet in mCSPC

First-line systemic therapy in patients with metastatic castration-sensitive prostate cancer should be based on individual disease and patient characteristics, results of a meta-analysis suggest.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Memorial Sloan Kettering Cancer Center ,Dana Farber Cancer Institute ,Howardi Scher ,Deaglanj Mchugh , ,Irbaz Bin Riaz ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Prostate ,Cancer ,Alignant Neoplasia ,Arcinoma ,Metastasis ,Meta Analysis ,Prostatic ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Chemotherapy ,Clinical Research ,Clinical Trials ,Linical Studies ,